PubMed · 7482811
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
T B Strom, A W Steele, J Nichols. 1995. Genetically engineered proteins for immunoregulation.. https://pubmed.ncbi.nlm.nih.gov/7482811/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Tumor cells have been found in autologous hematopoietic cell transplants used after high-dose chemotherapy. To specifically eliminate contaminating mammary tumor cells during ex vivo expansion of CD34+ hematopoietic progenitor cells, we used recombinant immunotoxins (ITs) directed against cell-surface antigens expressed on mammary carcinoma cells. ITs were expressed from fusion cDNAs combining a single-chain antibody fragment (scFv) directed against the Erb-B2 or epidermal growth factor (EGF) receptors with a truncated Pseudomonas exotoxin A fragment devoid of its cell-binding domain. CD34+ hematopoietic progenitor cells did not express Erb-B2 and EGF receptors as detected by Western blotting. Ex vivo expansion of total hematopoietic cells or of colony-forming cells from CD34+ progenitors in the presence of stem-cell factor (SCF), interleukin-1 (IL-1), IL-3, IL-6, and erythropoietin (Epo) was not affected when ITs were added to the cultures. In contrast, MDA-MB 453 and MCF-7 mammary carcinoma cells were depleted in a dose- and time-dependent manner by more than 3 log in coculture with CD34+ cells over a period of 7 days in the presence of 100 to 1,000 ng/mL of anti-Erb-B2 IT. This included elimination of the subpopulations with regrowth potential. Similarly, addition of either anti-Erb-B2 or anti-EGF receptor ITs to primary breast cancer cells isolated from patients with metastatic disease resulted in elimination of cytokeratin-positive cells in seven of seven samples. ITs are highly efficient and convenient to use for the depletion of mammary tumor cells during ex vivo expansion of hematopoietic progenitor-cell autografts.
G13 belongs to the G12 family of heterotrimeric G proteins, whose effectors are poorly defined. The present study was designed to test if phospholipase D (PLD) is regulated by G13 and if Rho-type small GTPases are involved. Expression of the constitutively active Q226L mutant of the alpha-subunit of G13 in COS-7 cells stimulated the activity of a rat brain phospholipase D isozyme (rPLD1) co-expressed in the cells. Wild type Galpha13 was ineffective unless the cells were incubated with AlF4-. rPLD1 was previously shown to be activated by constitutively active V14RhoA in COS-7 cells (Park, S. K., Provost, J. J., Bae, C. D., Ho, W. T., and Exton, J. H. (1997) J. Biol. Chem. 272, 29263-29272). When the endogenous Rho proteins of the cells were inactivated by treatment with C3 exoenzyme from Clostridium botulinum, the ability of Galpha13Q226L to activate rPLD1 was greatly attenuated. Co-transfection of dominant negative N19RhoA and N17Rac-1, but not N17Cdc42Hs or N17Ras, also inhibited the activation. Expression of constitutively active Galphaq in COS-7 cells also activated rPLD1, but constitutively active forms of Galphai2 and Galphas were without effect. These findings support an effector role for PLD in G13 signaling and demonstrate a requirement for Rho GTPases in this response.
We have shown previously that Rho plays a pivotal role in 1-oleoyl-lysophosphatidic acid (LPA)-dependent invasion of rat hepatoma cells (MM1). Herein we made stable transfectants of MM1 expressing active and Botulinum exoenzyme C3 (C3)-sensitive (Val14), or active and C3-insensitive (Val14/Ile41) forms of human RhoA. Both transfectants showed greatly promoted invasive ability in vitro in the absence of LPA as well as in vivo, adherence to the dish with scattered shape, and enhanced phosphorylation level of 20-kDa myosin light chain (MLC20). A specific MLC kinase inhibitor (KT5926) could inhibit their invasion and the phosphorylation level of MLC20. Stable active RhoA transfectants of W1 cells (low invasive counterpart of MM1) also demonstrated promoted invasive ability in vitro and in vivo, and enhanced phosphorylation level of MLC20. C3 treatment inhibited the invasiveness of the Val14 RhoA transfectant but not that of the Val14/Ile41 RhoA transfectant. LPA enhanced the invasiveness of both transfectants, and this enhancement was abolished by the C3 treatment. These results suggested that 1) the Rho signaling pathway and actomyosin system were linked in the transmigration of tumor cells, and 2) expressed active RhoA enhanced LPA-induced tumor cell invasion via the activation of endogenous RhoA pathway, indicating a positive feedback mechanism in the activation of RhoA.